Medicine Overview of Darzalex 400mg 1s
Uses of Darzalex 400mg 1s
Darzalex 400mg 1s side effects
How to use Darzalex 400mg 1s
How Darzalex 400mg 1s works
Monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. The binding to CD38 is believed to induce rapid tumor cell death through programmed cell death, or apoptosis, and multiple immune-mediated mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and antibody-dependent cellular cytotoxicity.
In Depth Information on Darzalex 400mg 1s
Expert advice for Darzalex 400mg 1s
- If infusion anaphylactic reaction or life-threatening reaction (Grade 4) occurs, institute appropriate care.
- Severe infusion reactions reported in ~50% of all patients (most during the first infusion); may also occur with subsequent infusions.
- Nearly all reactions occurred during infusion or within 4 hr of completing infusion.
- Prior to the introduction of postinfusion medication in clinical trials, infusion reactions occurred up to 48 hr after infusion.
- Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, and hypertension.
- Signs and symptoms may include respiratory symptoms (eg, cough, wheezing, larynx, throat tightness and irritation), laryngeal edema, pulmonary edema, nasal congestion, and allergic rhinitis.
- Less common symptoms were hypotension, headache, rash, urticaria, pruritus, nausea, vomiting, and chills.
- Premedicate patients with antihistamines, antipyretics, and corticosteroids.
- Frequently monitor patients during the entire infusion.
- Permanently discontinue for life-threatening (grade 4) reactions.
- For grade 1, 2, or 3 reactions, reduce the infusion rate when restarting the infusion.
- To reduce the risk of delayed infusion reactions, administer oral corticosteroids to all patients the first and second day after all infusions.
- Patients with a history of obstructive pulmonary disorders may require additional postinfusion medications to manage respiratory complications.
- Consider prescribing short- and long-acting bronchodilators and inhaled corticosteroids for patients with obstructive pulmonary disorders.
- May increase neutropenia or thrombocytopenia induced by background therapy; monitor CBC counts periodically during treatment; monitor patients with neutropenia for signs of infection; dose delay may be required to allow recovery of neutrophils; no dose reduction is recommended, consider supportive care with growth factors or transfusions.
Darzalex 400mg 1s related warnings
Special precautions for Darzalex 400mg 1s